WO2005085199A1 - Novel polymorphs of etoricoxib - Google Patents
Novel polymorphs of etoricoxib Download PDFInfo
- Publication number
- WO2005085199A1 WO2005085199A1 PCT/IN2005/000009 IN2005000009W WO2005085199A1 WO 2005085199 A1 WO2005085199 A1 WO 2005085199A1 IN 2005000009 W IN2005000009 W IN 2005000009W WO 2005085199 A1 WO2005085199 A1 WO 2005085199A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- etoricoxib
- novel
- novel polymorph
- ray diffraction
- diffraction pattern
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/22—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing two or more pyridine rings directly linked together, e.g. bipyridyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention describes novel forms of Etoricoxib, process for their preparation and pharmaceutical compositions containing them. More particularly, the present invention reveals new polymorphs of Etoricoxib, process for preparing them and various pharmaceutical compositions containing them. The present invention also describes the method of treatment of COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of the said novel polymorph and pharmaceutical composition containing them. The present invention relates to the use of novel polymorphs of Etoricoxib disclosed herein and pharmaceutical compositions containing them for the treatment of COX-2 mediated disorders.
- Etoricoxib is a selective COX-2 inhibitor which has been shown to be as effective as non-selective non-steroidal anti-inflammatory drugs in the management of chronic pain in rheumatoid arthritis, osteoarthritis and other COX-2 mediated disorders.
- Etoricoxib is 5-chloro-6'-methyl-3-[4-methylsulfonyl)phenyl]-2,3'-bipyridine having structural formula I.
- Etoricoxib is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.
- Etoricoxib belongs to a class of drugs known as COX-2 inhibitors that are used in the treatment of
- the present invention discloses eight different crystalline forms of Etoricoxib i.e Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV and Form XVI.
- the present invention provides new crystalline forms of Etoricoxib of formula I or mixture thereof.
- Another objective of the present invention is to provide a process for the preparation of the novel forms of Etoricoxib or mixture thereof.
- Yet another objective is to provide novel crystalline forms or there mixture of
- Etoricoxib which are stable. Yet another objective is to provide a process for the preparation of pharmaceutical composition comprising the said novel forms of Etoricoxib.
- compositions containing one or more of the new forms described in the present invention is provided.
- a further objective of the present invention is to provide uses of the novel forms of Etoricoxib for the treatment of COX-2 mediated disorders in a mammal including human.
- Fig 1 X-ray powder diffraction (XRD) pattern of novel form IX of Etoricoxib
- XRD X-ray powder diffraction
- the present invention provides novel crystalline forms of Etoricoxib which have different XRD patterns than so far known forms
- the novel forms of Etoricoxib are characterized by unique XRD pattern as shown in fig 1 to 8 which are different from various forms reported in application nos WO 01/92230, WO 96/10012 and WO 96/16934
- the present invention also discloses processes for the preparation of the said novel forms of Etoricoxib and pharmaceutical compositions containing them and their use in medicine particularly in the treatment of COX-2 mediated disorders
- the novel form IX of Etoricoxib may be prepared by a process comprising of the following steps a Preparing a solution of Etoricoxib in toluene at a suitable temperature selected in the range of 60 °C to 75 °C b Cooling the solution c Adding of an antisolvent selected from the group consisting of heptane, dusopropyl ether and the like or mixtures thereof (in two equal lots ) d Filtering and drying the separated solids to obtain Form IX of Etoricoxib
- Form IX is characterized by its unique XRD pattern as given in Fig 1
- the novel form X of Etoricoxib may be prepared by a process comprising of the following steps a Preparing a solution of Etoricoxib in toluene at a suitable temperature selected in the range of 60 °C to 75 °C b Cooling the solution c Isolating the product by adding suitable antisolvent heptane (in one lot) d Filtering and drying the separated solids to obtain Form X of Etoricoxib
- Form X is characterized by its unique XRD pattern as given in Fig 2
- the novel form XI of Etoricoxib may be prepared by a process comprising of the following steps a Preparing a solution of Etoricoxib in ethyl acetate or isopropyl acetate at room temperature b Filtering the reaction mixture c Concentrating the filtrate under reduced pressure to give solid residue, d Isolating the product by adding suitable antisolvent selected from the group consisting of hexane, dusopropyl ether and the like or mixtures thereof e Filtering and drying the separated solids to obtain Form XI of Etoricoxib
- Form XI is characterized by its unique XRD pattern as given in Fig 3
- the novel form XII of Etoricoxib may be prepared by a process comprising of the following steps a Preparing a solution of Etoricoxib in ethyl acetate at room temperature, b Filtering the reaction mixture c Concentrating the filtrate under reduced pressure to give solid residue d Isolating the product by adding suitable antisolvent hexane e Filtering and drying the separated solids to obtain the Form XII of Etoricoxib
- Form XII is characterized by its unique XRD pattern as given in Fig 4
- Preparation of Form XIII The novel form XIII of Etoricoxib may be prepared by a process comprising of the following steps:
- the novel form XIV of Etoricoxib may be prepared by a process comprising of the5 following steps: a. Preparing a solution of Etoricoxib in ethyl acetate at room temperature, and washed with water. b. Separating the organic layer and treating with silica-gel and charcoal0 c. Drying and concentrating under reduced pressure to get solid residue. d. Isolating the product by adding suitable antisolvent such as dusopropyl ether e. Filtering and drying the isolated product to obtain Form XIV of Etoricoxib.
- Form XIV is characterized by its unique XRD pattern as given in Fig 6.5
- the novel form XV of Etoricoxib may be prepared by a process comprising of the following steps: a. Preparing a solution of Etoricoxib in aqueous HC1 at atmospheric temperature. b. Treating the solution with toluene. c. Separating the aqueous layer, treating it with charcoal and filtering it. d. Isolating the material by basifying the filtrate using ammonia solution. e. Filtering and drying the residue to obtain the Form XV of Etoricoxib.
- Form XV is characterized by its unique XRD pattern as given in Fig 7.
- the novel form XVI of Etoricoxib may be prepared by a process comprising of the 5 following steps: a. Preparing a solution of Etoricoxib in isopropyl acetate at a temperature selected from the range 70-75 °C. b. Cooling the solution to 0 °C.
- Form XVI is characterised by its unique XRD pattern as given in Fig 8.
- compositions and formulations of the novel forms of 15 Etoricoxib of the present invention can be prepared by known processes.
- novel forms of Etoricoxib of the present invention is selected according to the usage and may vary as per the requirement of the patient.
- the novel forms of Etoricoxib of the present invention can be used for the treatment of 20 COX-2 mediated disorders such as osteoarthritis, rheumatoid arthritis, pain and inflammatory disorders in a mammal including human.
- the novel forms of Etoricoxib are characterized by unique XRD pattern which are different from the various forms previously reported.
- Etoricoxib (1 gm) was dissolved in toluene at a suitable temperature between the range from 60°C to 75°C (in different batches) and the solution was cooled. Then material was isolated with antisolvent such as heptane (one lot) to get the reaction mixture. The crystals were filtered and dried in an oven to constant weight to obtain form X of Etoricoxib (41% yield , 99.92 % purity).
- Etoricoxib (I gm) was dissolved in ethyl acetate or isopropyl acetate at atmospheric temperature. After that the reaction mixture was filtered through hyflow bed and the filtrate was concentrated under reduced pressure to obtain solid residue which was isolated by a solution of hexane: dusopropyl ether (1 : 1). The isolated residues were filtered and dried in an oven to constant weight to obtain form XI of Etoricoxib (82% yield , > 98% purity).
- Etoricoxib (1 gm) was dissolved in ethyl acetate or isopropyl acetate at atmospheric temperature. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain solid residue which was isolated by a solution of hexane. The isolated residues were filtered and dried in an oven to constant weight to obtain form XI of Etoricoxib (82% yield , > 98% purity).
- EXAMPLE 5 PREPARATION OF FORM -XII OF ETORICOXIB Pure Etoricoxib (1 gm) was dissolved in ethyl acetate at atmospheric temperature. After that the reaction mixture was filtered & concentrated under reduced pressure to give solid residue which was isolated by adding antisolvent hexane. The isolated residues were filtered and dried in an oven to constant weight to obtain form XII of Etoricoxib (85% yield , > 98% purity).
- Etoricoxib (1 gm) was dissolved in ethyl acetate at atmospheric temperature. The solution was washed with water and the organic layer was separated and treated with silica gel and charcoal, then dried and concentrated under reduced pressure to get solid residue. Antisolvent dusopropyl ether was used to isolate the product. The product was filtered and dried in an oven to constant weight to get form XIV of Etoricoxib (83% yield , > 98% purity).
- EXAMPLE 8 PREPARATION OF FORM -XV OF ETORICOXIB
- EXAMPLE 9 PREPARATION OF FORM -XVI OF ETORICOXIB
- Etoricoxib (1 gm) was dissolved in isopropyl acetate at suitable temperature between 70°C-75°C. Then the reaction mixture was cooled at 0°C to isolate the product. The product was filtered and dried in an oven to constant weight to get form XVI of Etoricoxib (60% yield , > 98% purity).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN39/MUM/2004 | 2004-01-14 | ||
IN39MU2004 | 2004-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005085199A1 true WO2005085199A1 (en) | 2005-09-15 |
Family
ID=34917511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000009 WO2005085199A1 (en) | 2004-01-14 | 2005-01-07 | Novel polymorphs of etoricoxib |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005085199A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010097802A2 (en) | 2009-02-27 | 2010-09-02 | Cadila Healthcare Limited | A process for the preparation of etoricoxib |
WO2011158250A1 (en) | 2010-06-16 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates |
WO2012004677A1 (en) | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
WO2012163839A1 (en) | 2011-05-27 | 2012-12-06 | Farma Grs, D.O.O. | A process for the preparation of polymorphic form i of etoricoxib |
WO2013075732A1 (en) * | 2011-11-21 | 2013-05-30 | Synthon Bv | Process for making crystalline form i of etoricoxib |
EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
WO2013105106A1 (en) | 2011-11-03 | 2013-07-18 | Cadila Healthcare Limited | An improved process for the preparation of etoricoxib and polymorphs thereof |
WO2013144977A2 (en) | 2012-03-30 | 2013-10-03 | Mylan Laboratories Ltd. | An improved process for the preparation of etoricoxib |
WO2014033526A1 (en) | 2012-08-27 | 2014-03-06 | Cadila Healthcare Limited | Pharmaceutical compositions of etoricoxib |
CN104418799A (en) * | 2013-09-03 | 2015-03-18 | 天津药物研究院 | Etoricoxib crystal as well as preparation method and application thereof |
CN107056691A (en) * | 2017-06-21 | 2017-08-18 | 四川尚锐生物医药有限公司 | A kind of method for preparing Etoricoxib crystal formation V |
WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
CN112826804A (en) * | 2019-11-22 | 2021-05-25 | 北京泰德制药股份有限公司 | Etoricoxib composition |
WO2022216975A1 (en) | 2021-04-09 | 2022-10-13 | Tremeau Pahrmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture and use thereof |
US11858909B2 (en) | 2021-04-09 | 2024-01-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO2001037833A1 (en) * | 1999-11-29 | 2001-05-31 | Merck Frosst Canada & Co. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
US20020147221A1 (en) * | 2000-05-26 | 2002-10-10 | Crocker Loius S. | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis |
-
2005
- 2005-01-07 WO PCT/IN2005/000009 patent/WO2005085199A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO2001037833A1 (en) * | 1999-11-29 | 2001-05-31 | Merck Frosst Canada & Co. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
US20020147221A1 (en) * | 2000-05-26 | 2002-10-10 | Crocker Loius S. | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis |
Non-Patent Citations (1)
Title |
---|
DAVIES I W ET AL: "A PRACTICAL SYNTHESIS OF A COX-2-SPECIFIC INHIBITOR", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 65, 2000, pages 8415 - 8420, XP002326845, ISSN: 0022-3263 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010097802A2 (en) | 2009-02-27 | 2010-09-02 | Cadila Healthcare Limited | A process for the preparation of etoricoxib |
EP2479166A1 (en) | 2009-02-27 | 2012-07-25 | Cadila Healthcare Limited | A process for the preparation of etoricoxib |
WO2011158250A1 (en) | 2010-06-16 | 2011-12-22 | Glenmark Generics Limited | Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates |
EP2582690A4 (en) * | 2010-06-16 | 2013-09-18 | Glenmark Generics Ltd | Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates |
WO2012004677A1 (en) | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
WO2012163839A1 (en) | 2011-05-27 | 2012-12-06 | Farma Grs, D.O.O. | A process for the preparation of polymorphic form i of etoricoxib |
WO2013105106A1 (en) | 2011-11-03 | 2013-07-18 | Cadila Healthcare Limited | An improved process for the preparation of etoricoxib and polymorphs thereof |
WO2013075732A1 (en) * | 2011-11-21 | 2013-05-30 | Synthon Bv | Process for making crystalline form i of etoricoxib |
EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
WO2013144977A3 (en) * | 2012-03-30 | 2013-12-12 | Mylan Laboratories Ltd. | An improved process for the preparation of etoricoxib |
WO2013144977A2 (en) | 2012-03-30 | 2013-10-03 | Mylan Laboratories Ltd. | An improved process for the preparation of etoricoxib |
WO2014033526A1 (en) | 2012-08-27 | 2014-03-06 | Cadila Healthcare Limited | Pharmaceutical compositions of etoricoxib |
CN104418799A (en) * | 2013-09-03 | 2015-03-18 | 天津药物研究院 | Etoricoxib crystal as well as preparation method and application thereof |
CN107056691A (en) * | 2017-06-21 | 2017-08-18 | 四川尚锐生物医药有限公司 | A kind of method for preparing Etoricoxib crystal formation V |
CN107056691B (en) * | 2017-06-21 | 2020-03-10 | 四川尚锐生物医药有限公司 | Method for preparing etoricoxib crystal form V |
WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
CN112826804A (en) * | 2019-11-22 | 2021-05-25 | 北京泰德制药股份有限公司 | Etoricoxib composition |
CN112826804B (en) * | 2019-11-22 | 2022-07-15 | 北京泰德制药股份有限公司 | Etoricoxib composition |
WO2022216975A1 (en) | 2021-04-09 | 2022-10-13 | Tremeau Pahrmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture and use thereof |
US11858909B2 (en) | 2021-04-09 | 2024-01-02 | Tremeau Pharmaceuticals, Inc. | Deuterated etoricoxib, methods of manufacture, and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005085199A1 (en) | Novel polymorphs of etoricoxib | |
JP7145931B2 (en) | Crystal polymorph of compound, its production method and use | |
JP5086069B2 (en) | Atazanavir bisulfate and process for producing novel forms | |
SE452322B (en) | Crystalline 1,1-DIOXOPENICILLANOYLOXIMETHYL-6- (D-ALFA-AMINO-ALFA-PHENYLACETAMIDO) PENICILLANATE-P-TOLUENESULPHONATE HYDRATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
TWI530500B (en) | Amorphous n-benzoyl-staurosporine, processes for the preparation, and use thereof | |
WO2011143872A1 (en) | Crystal form of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparation method and use thereof | |
EP1296951B1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3'] bipyridinyl in pure crystalline form and process for synthesis | |
CA2350956C (en) | New crystals of celecoxib | |
CN107207485A (en) | (S) crystal formation of the formamide of 5 benzyl N (base of 5 methyl, 4 oxo 2,3,4,5 tetrahydro benzo [b] [1,4] oxaza heptantriene 3) 1,2,4 triazoles of 4H 3 | |
WO1992017473A1 (en) | Crystalline tiagabine hydrochloride monohydrate, its preparation and use | |
RU2007109817A (en) | NEW POLYMORPHES OF AZABicyclohexane | |
WO2018109786A1 (en) | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives | |
JP6275644B2 (en) | N- [2-({2-[(2S) -2-cyanopyrrolidin-1-yl] -2-oxoethyl} amino) -2-methylpropyl] -2-methylpyrazolo [1,5-a] pyrimidine-6 -Carboxamide crystals | |
AU2016369653B2 (en) | Alkynyl dihydroquinoline sulfonamide compounds | |
JP2000516257A (en) | Tachykinin antagonist | |
EP1809631A1 (en) | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione | |
EP1858847A1 (en) | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions | |
WO1994029303A1 (en) | Heterocyclic chemistry | |
WO2014193881A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
JPH0211592A (en) | Optically active dihydropyridinephosphonic ester | |
JP2002527442A (en) | Imidazo-benzazepine with cardiovascular, anti-tumor, anti-infective and anti-inflammatory activities | |
US7538126B2 (en) | Crystalline forms of valdecoxib | |
JPH05117280A (en) | Amino acid-substituted thiazetoquinoline-3-carboxylic acid derivative | |
JP3001975B2 (en) | Crystalline tiagabine hydrochloride monohydrate, production method and use thereof | |
US3118906A (en) | 3-substituted-3-pyrrolidinols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |